Moreover, inhibition of mTOR, a downstream target of the PI3K pathway, has also been clinically shown to enhance the anticancer effect of endocrine therapy with AIs in HR+ advanced BC(Baselga et al., 2012). Here, PIK3CD is linked to breast cancer.